Literature DB >> 29148858

From bench to almost bedside: the long road to a licensed Ebola virus vaccine.

Gary Wong1,2,3,4, Emelissa J Mendoza3,5, Francis A Plummer4, George F Gao1,6, Gary P Kobinger3,4,5,7,8, Xiangguo Qiu3,4.   

Abstract

INTRODUCTION: The Ebola virus (EBOV) disease epidemic during 2014-16 in West Africa has accelerated the clinical development of several vaccine candidates that have demonstrated efficacy in the gold standard nonhuman primate (NHP) model, namely cynomolgus macaques. AREAS COVERED: This review discusses the pre-clinical research and if available, clinical evaluation of the currently available EBOV vaccine candidates, while emphasizing the translatability of pre-clinical data generated in the NHP model to clinical data in humans. EXPERT OPINION: Despite the existence of many successful EBOV vaccine candidates in the pre-clinical stages, only two platforms became the focus of Phase 2/3 efficacy trials in Liberia, Sierra Leone, and Guinea near the peak of the epidemic: the Vesicular stomatitis virus (VSV)-vectored vaccine and the chimpanzee adenovirus type 3 (ChAd3)-vectored vaccine. The results of three distinct clinical trials involving these candidates may soon pave the way for a licensed, safe and efficacious EBOV vaccine to help combat future epidemics.

Entities:  

Keywords:  Clinical trials; ebola virus; nonhuman primates; vaccines

Mesh：

Substances：

Year:  2017        PMID： 29148858      PMCID： PMC5841470          DOI： 10.1080/14712598.2018.1404572

Source DB:  PubMed          Journal:  Expert Opin Biol Ther        ISSN： 1471-2598            Impact factor:   4.388


  95 in total

1.  Nomenclature for immune correlates of protection after vaccination.

Authors:  Stanley A Plotkin; Peter B Gilbert
Journal:  Clin Infect Dis       Date:  2012-03-20       Impact factor: 9.079

2.  Ebola experts seek to expand testing.

Authors:  Declan Butler
Journal:  Nature       Date:  2014-12-11       Impact factor: 49.962

Review 3.  Acute lower respiratory tract infections in nonhospitalized children.

Authors:  F W Denny; W A Clyde
Journal:  J Pediatr       Date:  1986-05       Impact factor: 4.406

4.  An Adenovirus Vaccine Expressing Ebola Virus Variant Makona Glycoprotein Is Efficacious in Guinea Pigs and Nonhuman Primates.

Authors:  Shipo Wu; Andrea Kroeker; Gary Wong; Shihua He; Lihua Hou; Jonathan Audet; Haiyan Wei; Zhe Zhang; Lisa Fernando; Geoff Soule; Kaylie Tran; Shengli Bi; Tao Zhu; Xuefeng Yu; Wei Chen; Xiangguo Qiu
Journal:  J Infect Dis       Date:  2016-08-04       Impact factor: 5.226

5.  Development of a preventive vaccine for Ebola virus infection in primates.

Authors:  N J Sullivan; A Sanchez; P E Rollin; Z Y Yang; G J Nabel
Journal:  Nature       Date:  2000-11-30       Impact factor: 49.962

6.  Fruit bats as reservoirs of Ebola virus.

Authors:  Eric M Leroy; Brice Kumulungui; Xavier Pourrut; Pierre Rouquet; Alexandre Hassanin; Philippe Yaba; André Délicat; Janusz T Paweska; Jean-Paul Gonzalez; Robert Swanepoel
Journal:  Nature       Date:  2005-12-01       Impact factor: 49.962

7.  Safety and immunogenicity of Ebola virus and Marburg virus glycoprotein DNA vaccines assessed separately and concomitantly in healthy Ugandan adults: a phase 1b, randomised, double-blind, placebo-controlled clinical trial.

Authors:  Hannah Kibuuka; Nina M Berkowitz; Monica Millard; Mary E Enama; Allan Tindikahwa; Arthur B Sekiziyivu; Pamela Costner; Sandra Sitar; Deline Glover; Zonghui Hu; Gyan Joshi; Daphne Stanley; Meghan Kunchai; Leigh Anne Eller; Robert T Bailer; Richard A Koup; Gary J Nabel; John R Mascola; Nancy J Sullivan; Barney S Graham; Mario Roederer; Nelson L Michael; Merlin L Robb; Julie E Ledgerwood
Journal:  Lancet       Date:  2014-12-23       Impact factor: 79.321

8.  Ebola virus-like particle-based vaccine protects nonhuman primates against lethal Ebola virus challenge.

Authors:  Kelly L Warfield; Dana L Swenson; Gene G Olinger; Warren V Kalina; M Javad Aman; Sina Bavari
Journal:  J Infect Dis       Date:  2007-11-15       Impact factor: 5.226

9.  Immune protection of nonhuman primates against Ebola virus with single low-dose adenovirus vectors encoding modified GPs.

Authors:  Nancy J Sullivan; Thomas W Geisbert; Joan B Geisbert; Devon J Shedlock; Ling Xu; Laurie Lamoreaux; Jerome H H V Custers; Paul M Popernack; Zhi-Yong Yang; Maria G Pau; Mario Roederer; Richard A Koup; Jaap Goudsmit; Peter B Jahrling; Gary J Nabel
Journal:  PLoS Med       Date:  2006-05-16       Impact factor: 11.069

10.  Vesicular stomatitis virus-based ebola vaccine is well-tolerated and protects immunocompromised nonhuman primates.

Authors:  Thomas W Geisbert; Kathleen M Daddario-Dicaprio; Mark G Lewis; Joan B Geisbert; Allen Grolla; Anders Leung; Jason Paragas; Lennox Matthias; Mark A Smith; Steven M Jones; Lisa E Hensley; Heinz Feldmann; Peter B Jahrling
Journal:  PLoS Pathog       Date:  2008-11-28       Impact factor: 6.823
View more
  17 in total

1.  Ebola Virus Inclusion Body Formation and RNA Synthesis Are Controlled by a Novel Domain of Nucleoprotein Interacting with VP35.

Authors:  Tsuyoshi Miyake; Charlotte M Farley; Benjamin E Neubauer; Thomas P Beddow; Thomas Hoenen; Daniel A Engel
Journal:  J Virol       Date:  2020-07-30       Impact factor: 5.103

Review 2.  Postexposure Effects of Vaccines on Infectious Diseases.

Authors:  Tara Gallagher; Marc Lipsitch
Journal:  Epidemiol Rev       Date:  2019-01-31       Impact factor: 6.222

3.  Recombinant subunit vaccines protect guinea pigs from lethal Ebola virus challenge.

Authors:  Axel T Lehrer; Teri-Ann S Wong; Michael M Lieberman; Lisa Johns; Liana Medina; Friederike Feldmann; Heinz Feldmann; Andrea Marzi
Journal:  Vaccine       Date:  2019-07-16       Impact factor: 3.641

4.  Pseudovirus rVSVΔG-ZEBOV-GP Infects Neurons in Retina and CNS, Causing Apoptosis and Neurodegeneration in Neonatal Mice.

Authors:  Ian L McWilliams; Jennifer L Kielczewski; Derek D C Ireland; Jacob S Sykes; Aaron P Lewkowicz; Krishnamurthy Konduru; Biying C Xu; Chi-Chao Chan; Rachel R Caspi; Mohanraj Manangeeswaran; Daniela Verthelyi
Journal:  Cell Rep       Date:  2019-02-12       Impact factor: 9.423

5.  Pre-clinical development of a vaccine against Lassa fever.

Authors:  L Banadyga; D R Stein; X Qiu; D Safronetz
Journal:  Can Commun Dis Rep       Date:  2018-06-07

6.  Thermostable Ebola virus vaccine formulations lyophilized in the presence of aluminum hydroxide.

Authors:  Carly Fleagle Chisholm; Taek Jin Kang; Miao Dong; Kasey Lewis; Madhuri Namekar; Axel T Lehrer; Theodore W Randolph
Journal:  Eur J Pharm Biopharm       Date:  2019-01-28       Impact factor: 5.571

7.  Preexisting Virus-Specific T Lymphocytes-Mediated Enhancement of Adenovirus Infections to Human Blood CD14+ Cells.

Authors:  Fengling Feng; Jin Zhao; Pingchao Li; Ruiting Li; Ling Chen; Caijun Sun
Journal:  Viruses       Date:  2019-02-13       Impact factor: 5.048

8.  Exchange Protein Directly Activated by cAMP Modulates Ebola Virus Uptake into Vascular Endothelial Cells.

Authors:  Aleksandra Drelich; Barbara Judy; Xi He; Qing Chang; Shangyi Yu; Xiang Li; Fanglin Lu; Maki Wakamiya; Vsevolod Popov; Jia Zhou; Thomas Ksiazek; Bin Gong
Journal:  Viruses       Date:  2018-10-16       Impact factor: 5.048

9.  Lessons learned from Ebola Vaccine R&D during a public health emergency.

Authors:  Marie-Paule Kieny
Journal:  Hum Vaccin Immunother       Date:  2018-03-21       Impact factor: 3.452

Review 10.  Advances in Designing and Developing Vaccines, Drugs, and Therapies to Counter Ebola Virus.

Authors:  Kuldeep Dhama; Kumaragurubaran Karthik; Rekha Khandia; Sandip Chakraborty; Ashok Munjal; Shyma K Latheef; Deepak Kumar; Muthannan Andavar Ramakrishnan; Yashpal Singh Malik; Rajendra Singh; Satya Veer Singh Malik; Raj Kumar Singh; Wanpen Chaicumpa
Journal:  Front Immunol       Date:  2018-08-10       Impact factor: 7.561
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.